A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

NCT06118333 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: BL-B01D1
DRUG: capecitabine
DRUG: gemcitabine
DRUG: docetaxel

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]